Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LD78 beta-targeted deoxyribonucleic acid vaccine
- Development stage
- Preclinical
- Lead developer
- University of Oslo
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
LD78 beta-targeted deoxyribonucleic acid vaccine is an experimental DNA-based cancer vaccine designed for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Developed using the Vaccibody platform, the vaccine encodes a homodimeric fusion protein comprising three functional units: a targeting unit (the human chemokine LD78β, also known as CCL3L1), a dimerization unit (human IgG3 hinge and CH3 domains), and an antigenic unit (tumor-specific single-chain fragment variable, scFv). The mechanism of action involves the targeting of the idiotype antigen to antigen-presenting cells (APCs) via the chemokine receptors CCR1, CCR3, and CCR5. This targeted delivery, often combined with electroporation, enhances the induction of anti-idiotypic antibody and T-cell responses. The vaccine is particularly investigated for its potential as an 'off-the-shelf' therapeutic for patients expressing stereotyped B-cell receptors.
- Other names
- LD78β-targeted DNA vaccineCCL3L1-targeted DNA vaccineCCL-3L1-targeted DNA vaccineCCL 3L1-targeted DNA vaccinehuman chemokine-Id fusion DNA Vaccibody
02
Targets
CCR1CCR3 (C-C chemokine receptor type 3)CCR5 (C-C chemokine receptor type 5)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on LD78 beta-targeted deoxyribonucleic acid vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LD78 beta-targeted deoxyribonucleic acid vaccine.